LY 518674: a peroxisome proliferator-activated receptor alpha agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135449333 |
| CHEMBL ID | 424133 |
| SCHEMBL ID | 2669568 |
| MeSH ID | M0457997 |
| Synonym |
|---|
| gtpl2658 |
| 2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-2h-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid |
| ly-674 |
| ly-518674 |
| ly 518674 |
| 2-methyl-2-(4-{3-[1-(4-methyl-benzyl)-5-oxo-4,5-dihydro-1h-[1,2,4]triazol-3-yl]-propyl}-phenoxy)-propionic acid |
| bdbm50135780 |
| kb-68984 |
| CHEMBL424133 , |
| ly518674 |
| 2-methyl-2-(4-{3-(1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)propyl}phenoxy)propanoic acid |
| propanoic acid, 2-(4-(3-(2,5-dihydro-1-((4-methylphenyl)methyl)-5-oxo-1h-1,2,4-triazol-3-yl)propyl)phenoxy)-2-methyl- |
| u8i57rc739 , |
| unii-u8i57rc739 |
| 425671-29-0 |
| PNHFDVSKDSLUFH-UHFFFAOYSA-N , |
| 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1h-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl-propanoic acid |
| SCHEMBL2669568 |
| DB12988 |
| AKOS032947316 |
| 2-methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid |
| CS-0004237 |
| HY-50665 |
| Q27083211 |
| 2-methyl-2-(4-(3-(1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)propyl)phenoxy)propanoic acid |
| cid 9909438 |
| 2-methyl-2-[4-[3-[2-[(4-methylphenyl)methyl]-3-oxo-1h-1,2,4-triazol-5-yl]propyl]phenoxy]propanoic acid |
| 2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-4h-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid |
| MS-27052 |
| 2-methyl-2-[4-(3-{1-[(4-methylphenyl)methyl]-5-oxo-2,5-dihydro-1h-1,2,4-triazol-3-yl}propyl)phenoxy]propanoic acid |
| DTXSID10962564 |
| EX-A5645 |
| Excerpt | Reference |
|---|---|
| " After testing for selective and dual potency, off-target counter screening, metabolic stability, oral bioavailability and associated toxicity, compound 11, the first reported PPARα/δ dual antagonist was chosen for more advanced preclinical evaluation." | ( Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies. Baccei, CS; Bravo, Y; Broadhead, A; Chen, A; Correa, L; Fischer, K; Jacintho, JD; Laffitte, B; Lee, C; Lorrain, DS; Messmer, D; Prasit, P; Stebbins, KJ; Stock, NS, 2019) |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 6.5006 | 0.0050 | 1.2051 | 10.0000 | AID156956; AID665205 |
| Peroxisome proliferator-activated receptor delta | Homo sapiens (human) | IC50 (µMol) | 3.8009 | 0.0010 | 0.8505 | 6.3100 | AID156773; AID665204 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | IC50 (µMol) | 0.0240 | 0.0005 | 0.8269 | 6.3100 | AID156283; AID665203 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | EC50 (µMol) | 0.0420 | 0.0006 | 1.6074 | 10.0000 | AID1140788; AID1535336; AID156131 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1535336 | Agonist activity at human PPARalpha | 2019 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3 | Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies. |
| AID665205 | Agonist activity at PPARgamma | 2012 | Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11 | Activity landscape modeling of PPAR ligands with dual-activity difference maps. |
| AID115859 | Compound was evaluated in human apoA-I transgenic mice for maximal percent increase in HDL-cholesterol | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID665203 | Agonist activity at PPARalpha | 2012 | Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11 | Activity landscape modeling of PPAR ligands with dual-activity difference maps. |
| AID156131 | Cotransfection activity against human Peroxisome proliferator activated receptor alpha | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID114821 | Compound was evaluated in human apoA-I transgenic mice for its ability to alter serum triglyceride | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID156948 | Cotransfection activity of compound against human Peroxisome proliferator activated receptor gamma was determined at 10 uM | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID665204 | Agonist activity at PPARdelta | 2012 | Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11 | Activity landscape modeling of PPAR ligands with dual-activity difference maps. |
| AID1140788 | Agonist activity at human PPAR-alpha | 2014 | Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10 | Identification of the first potent, selective and bioavailable PPARα antagonist. |
| AID156773 | Inhibitory activity of compound against the binding of human Peroxisome proliferator activated receptor delta was determined | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID156618 | Cotransfection activity of compound against human Peroxisome proliferator activated receptor delta was determined at 10 uM | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID156956 | Inhibitory activity of compound against the binding of human Peroxisome proliferator activated receptor gamma was determined | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID156283 | Inhibitory activity against human Peroxisome proliferator activated receptor alpha | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID114820 | Compound was evaluated in human apoA-I transgenic mice for its ability to alter HDL-cholesterol levels | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2003 | Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24 | Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (25.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||